NASDAQ:HALO - Halozyme Therapeutics Stock Price, Price Target & More

$19.16 -0.41 (-2.10 %)

(As of 04/19/2018 04:00 PM ET)

Previous Close$19.57

Today's Range$19.05 - $19.76

52-Week Range$11.41 - $21.48

Volume644,519 shs

Average Volume1.06 million shs

Market Capitalization$2.85 billion

P/E Ratio43.49

Dividend YieldN/A

Beta1.87

About Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. Its products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. The company's pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs; in subcutaneous urography; and to enhance resorption of radiopaque agents. It also develops PEGylated recombinant human hyaluronidase for the treatment of pancreatic ductal adenocarcinoma, non-small cell lung cancer, gastric cancer, metastatic breast cancer, and cholangiocarcinoma and gall bladder cancer. In addition, the company develops PEGylated adenosine deaminase 2, an immune checkpoint inhibitor that targets adenosine. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; and Alexion Pharma Holding. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Receive HALO News and Ratings via Email

Sign-up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:HALO

CUSIP40637H10

Webwww.halozyme.com

Phone858-794-8889

Debt

Debt-to-Equity Ratio0.60%

Current Ratio3.89%

Quick Ratio3.85%

Price-To-Earnings

Trailing P/E Ratio43.49

Forward P/E Ratio-23.37

P/E GrowthN/A

Sales & Book Value

Annual Sales$316.61 million

Price / Sales8.70

Cash Flow$0.4402 per share

Price / Cash43.53

Book Value$1.46 per share

Price / Book13.12

Profitability

EPS (Most Recent Fiscal Year)$0.45

Net Income$62.97 million

Net Margins19.89%

Return on Equity89.83%

Return on Assets17.39%

Miscellaneous

Employees255

Outstanding Shares143,730,000

How to Become a New Pot Stock Millionaire

Halozyme Therapeutics (NASDAQ:HALO) Frequently Asked Questions

What is Halozyme Therapeutics' stock symbol?

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings data on Tuesday, February, 20th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping the Zacks' consensus estimate of $0.58 by $0.27. The biopharmaceutical company earned $189.60 million during the quarter, compared to the consensus estimate of $173.11 million. Halozyme Therapeutics had a net margin of 19.89% and a return on equity of 89.83%. Halozyme Therapeutics's quarterly revenue was up 386.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.21) EPS. View Halozyme Therapeutics' Earnings History.

When is Halozyme Therapeutics' next earnings date?

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for Halozyme Therapeutics.

What price target have analysts set for HALO?

8 brokers have issued 1-year price objectives for Halozyme Therapeutics' shares. Their predictions range from $7.00 to $29.00. On average, they anticipate Halozyme Therapeutics' stock price to reach $19.75 in the next twelve months. View Analyst Ratings for Halozyme Therapeutics.

Who are some of Halozyme Therapeutics' key competitors?

Some companies that are related to Halozyme Therapeutics include Spark Therapeutics (ONCE), China Biologic Products (CBPO), arGEN-X BV (ARGX), CRISPR Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), Editas Medicine (EDIT), Repligen (RGEN), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD), Iovance Biotherapeutics (IOVA), DBV Technologies (DBVT), Cellectis (CLLS), REGENXBIO (RGNX) and Adaptimmune Therapeutics (ADAP).

Who are Halozyme Therapeutics' key executives?

Halozyme Therapeutics' management team includes the folowing people:

Dr. Helen I. Torley M.B. Ch. B., M.R.C.P., Pres, CEO & Director (Age 55)
Ms. Laurie D. Stelzer, Sr. VP, CFO & Principal Accounting Officer (Age 50)
Mr. Harry J. Leonhardt, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 61)
Mr. Mark J. Gergen, Former Chief Operating Officer (Age 55)
Dr. Michael J. LaBarre Ph.D., Chief Scientific Officer and VP (Age 54)

Has Halozyme Therapeutics been receiving favorable news coverage?

Press coverage about HALO stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Halozyme Therapeutics earned a media sentiment score of 0.07 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.82 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Halozyme Therapeutics' stock price today?

One share of HALO stock can currently be purchased for approximately $19.16.

How big of a company is Halozyme Therapeutics?

Halozyme Therapeutics has a market capitalization of $2.85 billion and generates $316.61 million in revenue each year. The biopharmaceutical company earns $62.97 million in net income (profit) each year or $0.45 on an earnings per share basis. Halozyme Therapeutics employs 255 workers across the globe.

How can I contact Halozyme Therapeutics?

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]

MarketBeat Community Rating for Halozyme Therapeutics (HALO)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		272 (Vote Outperform)
Underperform Votes:		210 (Vote Underperform)
Total Votes:		482

MarketBeat's community ratings are surveys of what our community members think about Halozyme Therapeutics and other stocks. Vote "Outperform" if you believe HALO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HALO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Halozyme Therapeutics (NASDAQ:HALO) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

8 Wall Street analysts have issued ratings and price targets for Halozyme Therapeutics in the last 12 months. Their average twelve-month price target is $19.75, suggesting that the stock has a possible upside of 3.08%. The high price target for HALO is $29.00 and the low price target for HALO is $7.00. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.38	2.38	2.33	2.43
Ratings Breakdown:	1 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 3 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 2 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$19.75	$19.75	$18.6667	$16.7143
Price Target Upside:	3.08% upside	2.65% upside	2.78% downside	4.33% downside

Halozyme Therapeutics (NASDAQ:HALO) Consensus Price Target History

Price Target History for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/22/2018	BMO Capital Markets	Reiterated Rating	Market Perform -> Market Perform	$18.00 -> $19.00	Low
2/21/2018	Canaccord Genuity	Boost Price Target	Buy	$19.00 -> $21.00	High
2/21/2018	JPMorgan Chase	Reiterated Rating	Overweight -> Overweight	$19.00 -> $22.00	Low
1/24/2018	Deutsche Bank	Set Price Target	Buy	$21.00	Low
1/24/2018	Goldman Sachs	Initiated Coverage	Neutral -> Neutral	$20.00	High
11/22/2017	Barclays	Downgrade	Overweight -> Hold	$16.00 -> $19.00	N/A
10/16/2017	Piper Jaffray	Boost Price Target	Overweight -> Overweight	$26.00 -> $29.00	N/A
8/10/2017	Jefferies Group	Reiterated Rating	Underperform	$6.75 -> $7.00	High
1/6/2017	Citigroup	Downgrade	Buy -> Neutral		N/A
9/8/2016	Wells Fargo	Reiterated Rating	Buy		N/A

(Data available from 4/19/2016 forward)

Halozyme Therapeutics (NASDAQ:HALO) Earnings History and Estimates Chart

Earnings by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ:HALO) Earnings Estimates

2018 EPS Consensus Estimate: ($1.05)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.28)	($0.28)	($0.28)
Q2 2018	1	($0.27)	($0.27)	($0.27)
Q3 2018	1	($0.26)	($0.26)	($0.26)
Q4 2018	1	($0.24)	($0.24)	($0.24)

Halozyme Therapeutics (NASDAQ HALO) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/7/2018		($0.21)					N/A
2/20/2018	Q4 2017	$0.58	$0.85	$173.11 million	$189.60 million	View	Listen
11/7/2017	Q3 2017	$0.06	$0.0190	$58.95 million	$63.73 million	View	N/A
8/8/2017	Q2 2017	($0.25)	($0.23)	$31.76 million	$33.80 million	View	Listen
5/9/2017	Q1 2017	($0.25)	($0.26)	$30.79 million	$29.60 million	View	Listen
2/28/2017	Q416	($0.30)	($0.21)	$37.94 million	$39.00 million	View	Listen
11/7/2016	Q316	($0.27)	($0.23)	$34.43 million	$31.90 million	View	Listen
8/9/2016	Q216	($0.27)	($0.21)	$29.94 million	$33.30 million	View	N/A
5/9/2016	Q116	($0.20)	($0.16)	$29.65 million	$42.50 million	View	N/A
2/29/2016	Q415	($0.08)	$0.03	$37.06 million	$52.20 million	View	Listen
11/9/2015	Q315	($0.16)	($0.19)	$24.01 million	$20.80 million	View	N/A
8/10/2015	Q215	($0.09)	$0.02	$24.84 million	$43.40 million	View	Listen
5/11/2015	Q115	($0.13)	($0.12)	$19.40 million	$18.70 million	View	Listen
3/2/2015	Q414	($0.07)	($0.04)	$25.60 million	$30.38 million	View	N/A
11/10/2014	Q314	($0.14)	($0.16)	$16.50 million	$14.60 million	View	N/A
8/11/2014	Q214	($0.18)	($0.13)	$13.71 million	$18.40 million	View	N/A
5/12/2014	Q114	($0.14)	($0.22)	$13.37 million	$12.00 million	View	N/A
2/27/2014	Q413	($0.17)	($0.19)	$21.80 million	$12.50 million	View	N/A
11/8/2013	Q313	($0.15)	($0.17)	$14.62 million	$16.00 million	View	N/A
8/7/2013	Q2 2013	($0.13)	($0.13)	$11.29 million	$14.50 million	View	N/A
5/8/2013	Q1 2013	($0.15)	($0.17)	$7.05 million	$11.83 million	View	N/A
2/25/2013	Q4 2012	($0.16)	($0.04)	$7.32 million	$21.80 million	View	N/A
11/8/2012	Q312	($0.13)	($0.18)	$6.09 million	$5.33 million	View	N/A
8/6/2012		($0.15)	($0.13)			View	N/A
5/7/2012		($0.11)	$0.14			View	N/A
3/9/2012		($0.16)	($0.18)			View	N/A
11/7/2011		($0.03)	$0.05			View	N/A
8/5/2011	Q2 2011	($0.13)	$0.03			View	N/A
5/6/2011	Q1 2011	($0.13)	($0.10)			View	N/A
3/11/2011	Q4 2010	($0.12)	($0.17)			View	N/A
11/5/2010	Q3 2010	($0.13)	($0.13)			View	N/A
8/6/2010	Q2 2010	($0.14)	($0.13)			View	N/A
5/7/2010	Q1 2010	($0.16)	($0.13)			View	N/A
3/12/2010	Q4 2009	($0.16)	($0.14)			View	N/A
11/6/2009	Q3 2009	($0.18)	($0.16)			View	N/A
8/7/2009	Q2 2009	($0.16)	($0.21)			View	N/A
5/8/2009	Q1 2009	($0.15)	($0.18)			View	N/A
3/13/2009	Q4 2008	($0.13)	($0.21)			View	N/A
11/6/2008	Q3 2008	($0.14)	($0.14)			View	N/A
8/8/2008	Q2 2008	($0.13)	($0.14)			View	N/A
5/8/2008	Q1 2008	($0.12)	($0.13)			View	N/A
3/13/2008	Q4 2007	($0.09)	($0.11)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Halozyme Therapeutics (NASDAQ:HALO) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Halozyme Therapeutics (NASDAQ HALO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 16.80%
Institutional Ownership Percentage: 85.25%

Insider Trading History for Halozyme Therapeutics (NASDAQ:HALO)

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics (NASDAQ HALO) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/20/2015	Laurie Stelzer	CFO	Buy	10,000	$17.24	$172,400.00
6/18/2015	Kenneth J Kelley	Director	Sell	20,000	$21.00	$420,000.00
9/16/2014	David A Ramsay	CFO	Buy	25,000	$8.90	$222,500.00
9/16/2014	Helen Torley	CEO	Buy	50,000	$8.92	$446,000.00
8/19/2014	John Stuart Patton	Director	Sell	75,000	$9.96	$747,000.00
5/15/2014	Robert Engler	Director	Sell	126,700	$7.56	$957,852.00	233,176
9/16/2013	John Stuart Patton	Director	Sell	75,000	$9.13	$684,750.00	155,000
8/19/2013	H. Michael Shepard	VP	Sell	10,000	$7.11	$71,100.00
8/14/2013	Kathryn Falberg	Director	Buy	100,000	$6.82	$682,000.00	280,000
11/29/2012	Robert Engler	Director	Buy	15,000	$5.57	$83,550.00
11/14/2012	James P Shaffer	VP	Buy	20,000	$5.22	$104,400.00
11/13/2012	Kathryn E Falberg	Director	Buy	50,000	$5.21	$260,500.00
8/27/2012	Kenneth J Kelley	Director	Buy	20,000	$5.70	$114,000.00
8/13/2012	Gregory Ian Frost	CEO	Buy	2,000	$5.50	$11,000.00

(Data available from 1/1/2013 forward)

Halozyme Therapeutics (NASDAQ HALO) News Headlines

Source:

Date	Headline
	MabVax Therapeutics (MBVX) Announces Results of Antibody Program in Three Poster Presentations at 2018 AACR Meetings www.streetinsider.com - April 19 at 8:33 AM
	Canaccord Genuity Analysts Give Halozyme Therapeutics (HALO) a $16.00 Price Target www.americanbankingnews.com - April 15 at 8:22 PM
	Zacks: Brokerages Anticipate Halozyme Therapeutics, Inc. (HALO) Will Post Quarterly Sales of $29.54 Million www.americanbankingnews.com - April 13 at 1:58 AM
	Halozyme Therapeutics, Inc. (HALO) Expected to Post Earnings of -$0.21 Per Share www.americanbankingnews.com - April 11 at 9:16 PM
	Piper Jaffray Analysts Give Halozyme Therapeutics (HALO) a $20.00 Price Target www.americanbankingnews.com - April 10 at 10:31 PM
	Abzena Notes Termination Of Agreement With Halozyme Therapeutics www.lse.co.uk - April 10 at 8:49 AM
	Halozyme To Host First Quarter 2018 Financial Results Conference Call finance.yahoo.com - April 10 at 8:49 AM
	BRIEF-Abzena Gets Notice From Halozyme Of Termination Of Agreement www.reuters.com - April 9 at 8:44 AM
	Form DEFA14A HALOZYME THERAPEUTICS www.streetinsider.com - April 6 at 5:26 PM
	Halozyme Therapeutics, Inc. (HALO) Given Consensus Rating of "Hold" by Brokerages www.americanbankingnews.com - April 4 at 5:38 PM
	Halozyme Therapeutics (HALO) PT Raised to $18.00 www.americanbankingnews.com - April 1 at 9:46 AM
	Halozyme Therapeutics (HALO) Cut to "Hold" at BidaskClub www.americanbankingnews.com - March 30 at 2:18 PM
	$29.54 Million in Sales Expected for Halozyme Therapeutics, Inc. (HALO) This Quarter www.americanbankingnews.com - March 27 at 1:56 AM
	Halozyme Therapeutics (HALO) Upgraded to Buy by Zacks Investment Research www.americanbankingnews.com - March 26 at 5:58 PM
	Zacks: Analysts Expect Halozyme Therapeutics, Inc. (HALO) to Announce -$0.21 Earnings Per Share www.americanbankingnews.com - March 25 at 11:14 PM
	Halozyme Therapeutics (HALO) and Eisai (ESALY) Head-To-Head Survey www.americanbankingnews.com - March 24 at 7:14 AM
	Halozyme Therapeutics (HALO) Upgraded by TheStreet to "B-" www.americanbankingnews.com - March 24 at 12:28 AM
	Halozyme Therapeutics (HALO) Raised to Strong-Buy at BidaskClub www.americanbankingnews.com - March 23 at 7:56 PM
	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Halozyme Therapeutics, Inc. finance.yahoo.com - March 23 at 8:40 AM
	Halozyme Announces Nomination Of Directors For Reelection At 2018 Stockholder Meeting finance.yahoo.com - March 22 at 5:23 PM
	Halozyme Therapeutics (HALO) to Present Data From Six ... - StreetInsider.com www.streetinsider.com - March 16 at 8:38 AM
	Halozyme Therapeutics (HALO) to Present Data From Six Nonclinical Studies at AACR www.streetinsider.com - March 15 at 8:34 AM
	Halozyme To Present Data From Six Nonclinical Studies At American Association Of Cancer Research Annual Conference finance.yahoo.com - March 14 at 6:46 PM
	Global Antidiabetics Market Opportunities 2018: Eli Lilly, Boehringer Ingelheim, Novo Nordisk www.marketwatch.com - March 14 at 9:00 AM
	QCOM Jeffrey William Henderson Insider Trades for Qualcomm Inc. www.marketwatch.com - March 13 at 7:05 PM
	Halozyme Therapeutics, Inc. (HALO) Receives Consensus Rating of "Hold" from Brokerages www.americanbankingnews.com - March 10 at 5:41 PM
	Analysts Anticipate Halozyme Therapeutics, Inc. (HALO) to Post -$0.20 Earnings Per Share www.americanbankingnews.com - March 8 at 4:15 PM
	Senzar Asset Management LLC Has $10.89 Million Position in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 5 at 3:44 PM
	Halozyme Therapeutics, Inc. (HALO) Shares Sold by Kennedy Capital Management Inc. www.americanbankingnews.com - March 5 at 11:39 AM
	97,707 Shares in Halozyme Therapeutics, Inc. (HALO) Purchased by Schroder Investment Management Group www.americanbankingnews.com - March 5 at 9:40 AM
	Halozyme Therapeutics, Inc. (HALO) Stake Raised by Lombard Odier Asset Management Switzerland SA www.americanbankingnews.com - March 4 at 2:39 PM
	State of Wisconsin Investment Board Increases Stake in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 4 at 9:32 AM
	Halozyme Therapeutics, Inc. (HALO) Position Lifted by Swiss National Bank www.americanbankingnews.com - March 3 at 7:34 AM
	Bogle Investment Management L P DE Acquires New Stake in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 3 at 4:52 AM
	Sei Investments Co. Reduces Stake in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 2 at 7:06 AM
	Snyder Capital Management L P Has $47.95 Million Stake in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - March 1 at 7:02 PM
	Technical Perspectives on Biotech Stocks -- Global Blood Therapeutics, GlycoMimetics, Halozyme Therapeutics, and Idera Pharma www.prnewswire.com - March 1 at 6:46 AM
	Halozyme Therapeutics, Inc. (HALO) Shares Sold by Brown Advisory Inc. www.americanbankingnews.com - March 1 at 5:16 AM
	Schwab Charles Investment Management Inc. Purchases 90,500 Shares of Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - February 28 at 5:44 AM
	The Manufacturers Life Insurance Company Reduces Holdings in Halozyme Therapeutics, Inc. (HALO) www.americanbankingnews.com - February 27 at 4:13 PM
	Halozyme Therapeutics (HALO) Upgraded at BidaskClub www.americanbankingnews.com - February 24 at 11:58 AM
	Halozyme Therapeutics, Inc. (HALO) to Post Q1 2018 Earnings of ($0.28) Per Share, Jefferies Group Forecasts www.americanbankingnews.com - February 23 at 8:06 AM
	Halozyme Therapeutics, Inc. Forecasted to Post FY2022 Earnings of $0.69 Per Share (HALO) www.americanbankingnews.com - February 22 at 4:34 PM
	Halozyme Therapeutics (HALO) Price Target Increased to $19.00 by Analysts at BMO Capital Markets www.americanbankingnews.com - February 22 at 3:20 PM
	Surface Oncology Expands Board of Directors www.bizjournals.com - February 22 at 8:36 AM
	Today’s Research Reports on Stocks to Watch: Halozyme Therapeutics and Loxo Oncology finance.yahoo.com - February 22 at 8:36 AM
	Halozyme Therapeutics, Inc. 2017 Q4 - Results - Earnings Call Slides seekingalpha.com - February 21 at 5:16 PM
	Halozyme Therapeutics (HALO) Given New $21.00 Price Target at Canaccord Genuity www.americanbankingnews.com - February 21 at 3:46 PM
	Halozyme Therapeutics (HALO) Price Target Raised to $22.00 at JPMorgan Chase & Co. www.americanbankingnews.com - February 21 at 12:45 PM
	Halozyme Therapeutics (HALO) Posts Quarterly Earnings Results, Beats Expectations By $0.27 EPS www.americanbankingnews.com - February 21 at 9:21 AM

Halozyme Therapeutics (NASDAQ:HALO) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Halozyme Therapeutics (NASDAQ:HALO) Income Statement, Balance Sheet and Cash Flow Statement

Halozyme Therapeutics (NASDAQ HALO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff